| SFRP2 immunoreactivity | ||||
---|---|---|---|---|---|
Variable | n a | IRS 0 – 4 (%) | IRS > 4 (%) | R d | P e |
Total | 125 | 93 (74) | 32 (26) | Â | Â |
Clinicopathological factors | |||||
Age at diagnosis (median: 57 years; range 29 – 82 years) | |||||
   < 60 years | 69 | 49 (71) | 20 (29) | -0.103 | 0.255 |
   ≥ 60 years | 55 | 44 (80) | 11 (20) |  |  |
Tumor sizeb | Â | Â | Â | Â | Â |
   pT1 | 42 | 29 (69) | 13 (31) | -0.110 | 0.226 |
   pT2 – 4 | 81 | 64 (79) | 17 (21) |  |  |
Lymph node statusb | Â | Â | Â | Â | Â |
   pN0 | 62 | 41 (66) | 21 (34) | -0.194 | 0.033 |
   pN1 – 3 | 59 | 49 (83) | 10 (17) |  |  |
Histological grade | Â | Â | Â | Â | Â |
   G1 – G2 | 67 | 49 (73) | 18 (27) | -0.047 | 0.606 |
   G3 | 57 | 44 (77) | 13 (23) |  |  |
Histological type | Â | Â | Â | Â | Â |
   ductal | 98 | 73 (75) | 25 (26) | 0.024 | 0.796 |
   lobular | 9 | 9 (100) | 0 (0) |  |  |
   other | 14 | 9 (64) | 5 (36) |  |  |
Immunohistochemistry | |||||
Estrogen receptor status | Â | Â | Â | Â | Â |
   negative (IRSc 0 – 2) | 28 | 20 (71) | 8 (29) | -0.079 | 0.424 |
   positive (IRS 3 – 12) | 76 | 60 (79) | 16 (21) |  |  |
Progesterone receptor status | Â | Â | Â | Â | Â |
   negative (IRSc 0 – 2) | 72 | 55 (76) | 17 (24) | 0.048 | 0.611 |
   positive (IRS 3 – 12) | 43 | 31 (72) | 12 (28) |  |  |
Her2 | Â | Â | Â | Â | Â |
   negative (0, 1+) | 91 | 70 (77) | 21 (23) | 0.110 | 0.238 |
   positive (2+, 3+) | 26 | 17 (65) | 9 (35) |  |  |
p53 | Â | Â | Â | Â | Â |
   negative (< 5%) | 70 | 53 (76) | 17 (24) | 0.033 | 0.724 |
   positive (≥ 5%) | 44 | 32 (73) | 12 (27) |  |  |